$8.20 +0.29 (%) Xenoport Inc - NASDAQ

Dec. 19, 2014 | 04:00 PM

Partner Headlines

  1. Clinton Group Issues Release Reporting Availability of Proxy Materials for XenoPort Annual Meeting

    Benzinga | Apr. 25, 2014 | 11:50AM EST
  2. XenoPort Files Definitive Proxy Materials and Mails Letter to Stockholders

    Benzinga | Apr. 22, 2014 | 08:33AM EST
  3. US Stock Futures Tumble; All Eyes On P&G, Honeywell Earnings

    Benzinga | Jan. 24, 2014 | 07:04AM EST
  4. XenoPort Prices 12M Share Offering at $6.00/Share

    Benzinga | Jan. 24, 2014 | 05:45AM EST
  5. XenoPort to Offer 10M Shares Common Stock

    Benzinga | Jan. 21, 2014 | 06:05AM EST
  6. XenoPort Reports Feedback from FDA on XP23829

    Benzinga | Jan. 12, 2014 | 17:20PM EST
  7. XenoPort Responds to Clinton Group Call for New CEO

    Benzinga | Oct. 15, 2013 | 22:38PM EST
  8. Jeryl L Hilleman Named Ocera Therapeutics CFO

    Benzinga | Sep. 3, 2013 | 05:49AM EST
  9. XenoPort Inc. Reports Operating Results (10-Q)

    GuruFocus | Oct. 25, 2012 | 11:03AM EST
  10. UPDATE: Piper Jaffray Downgrades XenoPort to Neutral on Drug Commercialization Delays

    Benzinga | Oct. 12, 2012 | 08:39AM EST
  11. UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on XenoPort

    Benzinga | Oct. 5, 2012 | 04:03AM EST
  12. Socks Hitting 52-Week Highs

    Benzinga | Sep. 20, 2012 | 21:13PM EST
  13. XenoPort Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 8, 2012 | 09:22AM EST
  14. Social Media Outlook for Friday July 27 (NYT, XNPT, GDOT, STRA)

    Benzinga | Jul. 27, 2012 | 09:02AM EST
  15. XenoPort Announces Pricing of Public Offering of 6.15M Shares at $6.50

    Benzinga | Jul. 26, 2012 | 02:21AM EST
  16. XenoPort Announces Proposed Public Offering of Common Stock

    Benzinga | Jul. 25, 2012 | 10:10AM EST
  17. XenoPort Announces Initiation of a Phase 1 Clinical Trial of XP23829, a Novel Fumarate Analog for the Potential Treatment of Relapsing-Remitting Multiple Sclerosis and Psoriasis

    Benzinga | Jul. 23, 2012 | 10:06AM EST
  18. From Earlier, GSK and XenoPort Receive FDA Approval for Horizant® for Postherpetic Neuralgia

    Benzinga | Jun. 7, 2012 | 01:54AM EST
  19. UPDATE: Credit Suisse Initiates Outperform, $7 PT on XenoPort; Valuation Trumps Fundamental Concerns

    Benzinga | Jun. 7, 2012 | 01:47AM EST
  20. Xenoport Cuts 18 Jobs, Sees Charges of 1.4M, Names Vincent Angotti Operating Chief

    Benzinga | Jun. 4, 2012 | 11:01AM EST
  21. UPDATE: Deutsche Bank Lowers Target on XenoPort to $7

    Benzinga | Feb. 16, 2012 | 01:13AM EST
  22. Wedbush Lowers PT on XenoPort to $15

    Benzinga | Dec. 31, 0000 | 19:00PM EST
Trading Center